Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[What's new in research?]

F Caux1

  • 1Centre de référence des dermatoses bulleuses auto-immunes et centre de référence des maladies génétiques à expression cutanée, service de dermatologie, hôpital Avicenne, AP-HP, 125, rue de Stalingrad, 93000 Bobigny ; INSERM UMR 1125, université Paris 13, 74, rue Marcel Cachin, 93000 Bobigny, France.

Annales De Dermatologie Et De Venereologie
|December 26, 2018
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Brunsting-Perry pemphigoid simulating squamous cell carcinoma.

Annales de dermatologie et de venereologie·2026
Same author

French national protocol for diagnosis and management of pemphigoid gestationis.

Annales de dermatologie et de venereologie·2026
Same author

A retrospective study on the liver toxicity of oral retinoids in Chanarin-Dorfman syndrome.

Journal of the European Academy of Dermatology and Venereology : JEADV·2023
Same author

Lobular panniculitis and diffuse osteonecrosis occurring during anti-MEK and anti-BRAF combination therapy for metastatic melanoma.

Journal of the European Academy of Dermatology and Venereology : JEADV·2023
Same author

Bronchial involvement in mucous membrane pemphigoid: 2 cases and a literature review.

Annales de dermatologie et de venereologie·2022
Same author

Updated S2 K guidelines for the management of bullous pemphigoid initiated by the European Academy of Dermatology and Venereology (EADV).

Journal of the European Academy of Dermatology and Venereology : JEADV·2022
Same journal

2024 guidelines (S3) for the therapeutic management of patients with genital herpes.

Annales de dermatologie et de venereologie·2026
Same journal

Topical JAK inhibitors in the lichen planus spectrum: a systematic review.

Annales de dermatologie et de venereologie·2026
Same journal

2024 recommendations for the therapeutic management of anogenital warts.

Annales de dermatologie et de venereologie·2026
Same journal

Successful use of thalidomide in treating metastatic Crohn's disease.

Annales de dermatologie et de venereologie·2026
Same journal

Multiple cutaneous juvenile xanthogranuloma: a monocentric study.

Annales de dermatologie et de venereologie·2026
Same journal

Cartilage-hair-hypoplasia associated with granulomatosis induced by rubella vaccine.

Annales de dermatologie et de venereologie·2026
See all related articles

This review highlights key 2017-2018 dermatology research, focusing on microbiome roles in anti-PD-1 response and autoimmunity, PI3Kδ inhibitors for autoimmune bullous diseases, and advancements in gene editing and cell therapies.

Area of Science:

  • Dermatology
  • Immunology
  • Genetics

Background:

  • Annual review of dermatology literature from 2017-2018.
  • Focus on advancements relevant to clinical practice and research.

Purpose of the Study:

  • Summarize significant findings in selected areas of dermatology.
  • Provide an overview of emerging therapeutic and diagnostic strategies.

Main Methods:

  • Literature review of scientific publications from 2017-2018.
  • Selection based on relevance to dermatology, autoimmunity, and genetics.

Main Results:

  • Key areas include microbiome in anti-PD-1 response and autoimmunity.
  • PI3Kδ inhibitors show promise in autoimmune bullous diseases.
Keywords:
Autoimmune bullous diseasesCAR-T cellsCRISPR/CasCellules CAR-TGene therapyMaladies bulleuses auto-immunesMicrobiomeTargeted therapyThérapie géniqueThérapies ciblées

Related Experiment Videos

  • CRISPR/Cas, CAR-T cells, gene therapy, targeted therapies, and genetics in primary care are discussed.

    • Conclusions:

    • Significant progress in understanding the microbiome's role in immune responses.
    • Emerging therapies like PI3Kδ inhibitors, CAR-T cells, and gene therapy offer new treatment avenues.
    • Integration of genetics into dermatological care is increasingly important.